logo
Reading Horizons Helps Highland East 8th Graders Gain On Average 2.5 Years of Reading Growth in Just One School Year

Reading Horizons Helps Highland East 8th Graders Gain On Average 2.5 Years of Reading Growth in Just One School Year

Business Wire28-05-2025
KAYSVILLE, Utah--(BUSINESS WIRE)--Highland East Junior High students, part of Moore Public Schools in Oklahoma, have made significant literacy gains, averaging an average 2.5 years of reading growth in a single academic year. These results come after several years of implementing Reading Horizons® Elevate, a structured literacy program grounded in the science of reading and designed for older students.
100% of the 8th-grade students in Shelly Hankins's reading class improved by at least 1.2 grade levels in reading proficiency, and most averaged 2.5 years of growth.
Veteran educator Shelly Hankins, who has taught reading since 1999, was initially skeptical when first asked to implement the program. Today, after seeing remarkable gains in both student confidence and achievement, she describes the experience as 'one of the most impactful years' of her teaching career.
'Some students didn't even know all their letter sounds at the start of the year,' said Hankins. 'We started from the ground up. I ensured they understood why we were returning to basics—we were building the foundation so they could succeed in high school and beyond. Making it fun—with games and a little competition—gave them a reason to engage. The program provided the structure, and the students brought the energy.'
This year, 100% of the 8th-grade students in Shelly Hankins' reading class improved by at least 1.2 grade levels in reading proficiency, and most averaged 2.5 years of growth. One student, who began the year reading at a 5.6 reading level, progressed to an 11th-grade level—a gain of over five grade levels by year's end.
Hankins' implementation of Reading Horizons Elevate involved:
Daily small-group instruction
Fluency passages and independent reading to build stamina
A structured 'proving' method for decoding multisyllabic words
These practices helped students grow academically and emotionally, boosting their confidence and independence as readers.
Science-Backed Instruction with Real Results
Reading Horizons® Elevate supports students in grades 4–12 who need targeted instruction in foundational reading skills, including decoding, phonics, and fluency. Grounded in the science of reading research, the program offers explicit, systematic instruction in flexible formats, including teacher-led, blended, and intervention settings. Across the country, educators use Reading Horizons Elevate across diverse learning environments from general education to special education, multilingual, and alternative education programs.
'Shelly's success is exactly what we designed Elevate to deliver—real, measurable growth for older learners with skill gaps, and the support educators need to drive that growth,' said Trisha Thomas, President at Reading Horizons.
The growth seen within this class of 8th graders reflects not only the strength of the program but also the dedication of Shelly Hankins and the Highland East administration. Their shared commitment to evidence-based instructional practices continues to strengthen academic outcomes and expand opportunities for all learners. It's a powerful way to close the school year—marking a strong finish —for the school and students.
For more information, explore how this achievement came to life in the classroom by exploring an in-depth Q&A with educator Shelly Hankins: ' How One Junior High Teacher Led Her 8th Grade Students to an Average 2.5-Year Reading Gain This Year.'
About Reading Horizons
For over 40 years, Reading Horizons® has equipped educators to eradicate illiteracy with innovative, tech-enabled foundational reading instruction. By aligning with the latest research in the science of reading, it supports educators, schools, and students with effective literacy solutions. Learn more about K–12 foundational literacy solutions and join the Science of Reading Collective, a collaborative space where educators share best practices and engage in meaningful discussions on literacy instruction.
About Moore Public Schools
Moore Public Schools is the fourth-largest district in Oklahoma, serving 24,500+ students and their families. MPS operates 25 elementary schools, six junior highs, three high schools, and one alternative school site. Learn more about MPS at www.mooreschools.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cade Prize for Inventivity Names 2025 Finalists
Cade Prize for Inventivity Names 2025 Finalists

Business Wire

time4 hours ago

  • Business Wire

Cade Prize for Inventivity Names 2025 Finalists

GAINESVILLE, Fla.--(BUSINESS WIRE)--Judges for the 16th Annual Cade Prize for Inventivity named this year's fifteen finalists. Finalists will compete to win $10,000 in their respective categories — Environmental, Healthcare, Technology, Sports, and Wildcard — and will compete in the final round of live judging at the awards ceremony on Tuesday, October 14 at the Cade Museum for Creativity and Invention in Gainesville, Florida. 'We're particularly excited by the addition of a Sports category to this year's competition. Athletic innovation is part of our origin story, and we're happy to officially welcome it to the Cade Prize.' — Richard Miles Share At the event, finalists will mingle with attendees, show off their innovations in an expo-style format, and meet one-on-one with the judges. After a round of live judging, the winners of the categories will be announced and the final five will present their pitches live on stage to compete for the Grand Prize of $50,000, the Student Choice Award, and free product consulting and legal services. This year's finalists include: Environmental Chemergy of Miami, Fla. for their HyBrTec system that produces renewable hydrogen, green carbon dioxide and heat from the elimination of organic and plastic waste generated by municipalities. EZ Ag Innovations of Lakeland, Fla. for Smart Spray Systems, a tractor-pulled, smart spray technology for specialty crop farmers that detects, identifies, and localizes pests or crops and applies pest management tools only where needed. Quornix of Bloomington, Ind. for pioneering anti-virulence therapeutics to combat Vibrio-related bacterial diseases in aquaculture and human health. Healthcare CasNx of Gainesville, Fla. for their CRISPR technology that help patients get safer organ transplants by genome-editing donor organs before surgery to make them virus-free, immune-silent, and more durable. Elias Sayour, M.D., Ph.D., from the University of Florida and Adam Grippin, M.D., Ph.D. from the University of Texas for their methods for sensitizing cancer immunotherapeutic response. NanoNeurosciences of Alachua, Fla. for NanoGlaucoOut, a platform for advanced peptide-based nanomedicines to treat conditions such as Glaucoma, Epilepsy, and Depression. Technology CoFlow Jet Lift of Miami, Fla. for Jetsail, their rigid wind sail technology that reduces fuel consumption for large maritime shipping vessels. Flashpoint Building Systems of Boise, Idaho for their Integrated Layout System, a pre-printed, full-floor layout solution for the construction industry. Immunogenik of Gainesville, Fla. for 8R-70CAR, a CD70-targeted CAR T cell therapy designed to treat aggressive, treatment-resistant cancers such as GBM, pediatric high-grade gliomas, and brain metastases. Sports Boss Helmet of Jacksonville, Fla. for their helmet designed to reduce head injuries for football players. Mud Rat of Storrs, Conn. for developing eco-friendly biomaterials for the marine and action sports industries. Puttrax of Orlando, Fla. for creating Puttrax 360, a portable training & gaming system for golf players. Wildcard Crypto Tutors of Orlando, Fla. for DeFi All Odds, a platform to help people pursue careers in blockchain technology. Floe of New Haven, Conn. for their automated ice and snow prevention system for commercial and residential buildings. VASA Pet of Tampa, Fla. for their pump-free, dishwasher-safe waterwheel pet fountain. As a national competition, the Cade Prize received a total of 100 applications from inventors and entrepreneurs from 16 states and with affiliations ranging from research universities to the private sector and technology transfer organizations. ' We're particularly excited by the addition of a Sports category to this year's competition. Athletic innovation is part of our origin story, and we're happy to officially welcome it to the Cade Prize.' — Richard Miles, Cade Museum Co-founder and Cade Prize Judge Final judging will take place at the awards ceremony on Tuesday, October 14 from 6:00 p.m. to 8:30 p.m. at the Cade Museum for Creativity and Invention. Tickets are on sale at This year's prize is sponsored by The Community Foundation of North Central Florida, The Florida High Tech Corridor, Gatorade, Cyle Sage, Greater Gainesville Chamber of Commerce, OneSixOne Ventures, Saliwanchik, Lloyd & Eisenschenk, 3D Musketeers, NVision Strategies and Hyatt Place Downtown. The Cade Prize for Inventivity — named after Dr. Robert Cade, lead inventor behind Gatorade — celebrates inventors and entrepreneurs, who, through an innovative invention, demonstrate a creative approach to addressing problems in their field of expertise. Learn more at

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

Yahoo

time4 hours ago

  • Yahoo

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass., August 21, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Collaboration is at the core of the Quanterix Accelerator Laboratory," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners." The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About QuanterixQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at View source version on Contacts Media Contact Marissa Klaassenmedia@ Sign in to access your portfolio

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

Business Wire

time6 hours ago

  • Business Wire

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' Share 'Collaboration is at the core of the Quanterix Accelerator Laboratory,' said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. 'Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners.' The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa ® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa ® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa ® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store